Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Emergent Biosolutions Inc. (EBS) had Revenue of $222.20M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$222.20M
Net Income	$68.00M
Cost of Goods Sold	$88.50M
Gross Profit	$133.70M
Operating Expenses	$172.30M
Operating Income	$49.90M
Non-Operating Income/Expense	$42.80M
Pre-Tax Income	$92.70M
Normalized Pre-Tax Income	$92.70M
Income after Taxes	$68.00M
Income from Continuous Operations	$68.00M
Consolidated Net Income/Loss	$68.00M
Normalized Income after Taxes	$68.00M
EBIT	$49.90M
EBITDA	$77.60M
Weighted-Average Shares Outstanding (Basic)	54.40M
Weighted-Average Shares Outstanding (Diluted)	57.30M
Earnings per Share (EPS) (Basic)	$1.25
Earnings per Share (EPS) (Diluted)	$1.19
Balance Sheet Financials
Current Assets	$706.80M
Property, Plant, and Equipment	$221.00M
Long-Term Assets	$719.30M
Total Assets	$1.43B
Current Liabilities	$111.90M
Long-Term Debt	$665.70M
Long-Term Liabilities	$761.50M
Total Liabilities	$873.40M
Common Equity	$552.70M
Tangible Shareholders Equity	$67.50M
Shareholders Equity	$552.70M
Common Shares Outstanding	54.50M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-11.20M
Cash Flow from Investing Activities	$59.50M
Cash Flow from Financial Activities	$-0.40M
Beginning Cash	$105.60M
End Cash	$152.80M
Increase/Decrease in Cash	$47.20M
Stock-Based Compensation	$1.50M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	6.32
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.55
Debt to Equity Ratio	1.20
Gross Margin	60.17%
Operating Margin	22.46%
EBIT Margin	22.46%
EBITDA Margin	--
Pre-Tax Profit Margin	41.72%
Profit Margin	30.60%
Free Cash Flow	$23.30M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.16
Inventory Turnover	0.28
Receiveable Turnover	1.09
Days Sales in Receivables	82.51
Return on Equity	12.30%
Return on Tangible Equity	100.74%
Return on Assets	4.77%
Return on Investments	5.58%
Book Value Per Share	$10.14
Free Cash Flow per Share	$0.41
Operating Cash Flow per Share	$-0.20

Data from Zacks Investment Research, Inc.